213 related articles for article (PubMed ID: 37398559)
1. Factors Associated With Genotypic Resistance and Outcome Among Solid Organ Transplant Recipients With Refractory Cytomegalovirus Infection.
Tamzali Y; Pourcher V; Azoyan L; Ouali N; Barrou B; Conti F; Coutance G; Gay F; Tourret J; Boutolleau D
Transpl Int; 2023; 36():11295. PubMed ID: 37398559
[TBL] [Abstract][Full Text] [Related]
2. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
[TBL] [Abstract][Full Text] [Related]
3. Emergence of letermovir resistance in solid organ transplant recipients with ganciclovir resistant cytomegalovirus infection: A case series and review of the literature.
Hofmann E; Sidler D; Dahdal S; Bittel P; Suter-Riniker F; Manuel O; Walti LN; Hirzel C
Transpl Infect Dis; 2021 Jun; 23(3):e13515. PubMed ID: 33210830
[TBL] [Abstract][Full Text] [Related]
4. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
Bruminhent J; Rotjanapan P; Watcharananan SP
Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
[TBL] [Abstract][Full Text] [Related]
6. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
[TBL] [Abstract][Full Text] [Related]
7. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.
Timpone JG; Yimen M; Cox S; Teran R; Ajluni S; Goldstein D; Fishbein T; Kumar PN; Matsumoto C
Transpl Infect Dis; 2016 Apr; 18(2):202-9. PubMed ID: 26853894
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.
Isada CM; Yen-Lieberman B; Lurain NS; Schilz R; Kohn D; Longworth DL; Taege AJ; Mossad SB; Maurer J; Flechner SM; Mawhorter SD; Braun W; Gordon SM; Schmitt SK; Goldman M; Long J; Haug M; Avery RK
Transpl Infect Dis; 2002 Dec; 4(4):189-94. PubMed ID: 12535261
[TBL] [Abstract][Full Text] [Related]
9. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease.
Belga S; Hernandez C; Kabbani D; Cervera C
Transpl Infect Dis; 2024 Apr; 26(2):e14227. PubMed ID: 38180285
[TBL] [Abstract][Full Text] [Related]
10. New developments in the management of cytomegalovirus infection after solid organ transplantation.
Eid AJ; Razonable RR
Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
[TBL] [Abstract][Full Text] [Related]
11. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
12. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Kim JM; Kwon CH; Joh JW; Ha YE; Sinn DH; Choi GS; Peck KR; Lee SK
PLoS One; 2015; 10(5):e0123554. PubMed ID: 25942443
[TBL] [Abstract][Full Text] [Related]
13. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
Razonable RR
Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
[TBL] [Abstract][Full Text] [Related]
14. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
Bixby AL; Fitzgerald L; Park JM; Kaul D; Tischer S
Transpl Infect Dis; 2021 Oct; 23(5):e13713. PubMed ID: 34428337
[TBL] [Abstract][Full Text] [Related]
15. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
Martin M; Goyette N; Ives J; Boivin G
J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
[TBL] [Abstract][Full Text] [Related]
16. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
[TBL] [Abstract][Full Text] [Related]
18. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection.
Mehta Steinke SA; Alfares M; Valsamakis A; Shoham S; Arav-Boger R; Lees L; Ostrander D; Forman MS; Shedeck A; Ambinder RF; Jones RJ; Avery RK
Transpl Infect Dis; 2021 Jun; 23(3):e13521. PubMed ID: 33220125
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients.
Martinez S; Sindu D; Nailor MD; Cherrier L; Tokman S; Walia R; Goodlet KJ
Transpl Infect Dis; 2024 Jun; 26(3):e14279. PubMed ID: 38742601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
